MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES

EHA Library, Antonio Galleu, 182104

INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

EHA Library, Aaron Weigl, 182099

LETERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)

EHA Library, Rafael Duarte, 182094

GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES

EHA Library, Laura Escribà, 182103

VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL

EHA Library, Stephan Stilgenbauer, 182058

EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY

EHA Library, Pier Luigi Zinzani, 182063

UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT

EHA Library, Gianluca De Rosa, 182098

LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY

EHA Library, Charlotte Pawlyn, 182068

PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

EHA Library, C Harrison, 182073

INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM

EHA Library, Linda Cheyenne Vaccari, 182093

MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY

EHA Library, Charles Craddock, 182078

IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE

EHA Library, Livia Giannoni, 182083

MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM

EHA Library, Monika Brüggemann, 182088

PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

EHA Library, Anna Lucia Fedullo, 182087

GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, Zinaida Peric, 182082

CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAA RANDOMIZED STUDY BY THE SWEDISH CLL GROUP

EHA Library, Tobias Svensson, 182092

FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70

EHA Library, Ana Garrido, 182077

PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY

EHA Library, Jason R. Gotlib, 182072

IDENTIFICATION OF GUANOSINE 5ʹ-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY

EHA Library, Stanzin angmo, 182097

TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)

EHA Library, PAUL RICHARDSON, 182067

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

EHA Library, Wolfgang Hiddemann, 182062

CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY

EHA Library, Nicholas HUNTINGTON, 182102

THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY

EHA Library, Peter Hillmen, 182057

IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Masafumi Seki, 182086

DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)

EHA Library, Ildefonso Espigado, 182091

21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)

EHA Library, Karl Staser, 182081

LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY

EHA Library, Marius Flasinski, 182076

LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.

EHA Library, Sandro Altamura, 182096

RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL

EHA Library, Martin Greisshammer, 182071

PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA

EHA Library, Irene Ghobrial, 182066

A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL

EHA Library, Mark WALTERS, 182101

COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY

EHA Library, Judith Trotman, 182061

IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP

EHA Library, Carol Moreno, 182056

NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA

EHA Library, I-Jun Lau, 181827

CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA

EHA Library, Sneha CHITRE, 181828

TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML

EHA Library, Iris Uras, 181829

CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.

EHA Library, Mayte Medrano, 181830

PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Elisa Sala, 181831

AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?

EHA Library, Victoria Prassek, 181833

GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE

EHA Library, Daniel J. DeAngelo, 181834

BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY

EHA Library, Tsila Zuckerman, 181835

FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES

EHA Library, Claudia Haferlach, 181836

COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)

EHA Library, Kiyomi Morita, 181837

THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY

EHA Library, Daehun kwak, 181838

VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML

EHA Library, Eunice Wang, 181839

PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH '7+3' DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD

EHA Library, Dr. Medhavi Gupta, 181840

VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.

EHA Library, Joan Ballesteros, 181841

RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS > 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP

EHA Library, Haifa Kathrin Al-Ali, 181842

OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY

EHA Library, Jeffrey Lancet, 181843

HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA

EHA Library, Sarah Bertoli, 181844

T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT

EHA Library, Long Liu, 181793

PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY

EHA Library, Sigrid Machherndl-Spandl, 181846

EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB

EHA Library, Mark Levis, 181847

CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Daehun kwak, 181848

INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML

EHA Library, Jorge Cortes, 181849

COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

EHA Library, Matthew A. Lunning, 181850

VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Matthew S. Davids, 181851

WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA

EHA Library, Katja De Paepe, 181852

PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.

EHA Library, Joost Vermaat, 181854

HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY

EHA Library, Marcus Hentrich, 181855

RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA

EHA Library, Deok-Hwan Yang, 181856

LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.

EHA Library, Francesca Farina, 181857

PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.

EHA Library, Catherine Scholz, 181858

BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).

EHA Library, Jérôme Jérôme, 181859

ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Raúl Teruel, 181860

SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA

EHA Library, Francesca Fioredda, 181862

TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS

EHA Library, Constantijn halkes, 181863

EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML

EHA Library, James Smith, 181826

THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES

EHA Library, Adil Al Hinai, 181825

GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA

EHA Library, June Takeda, 181824

P38Β MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA

EHA Library, Elena Arriazu, 181823

VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB

EHA Library, Mridul Agrawal, 181822

GFI1B - A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS

EHA Library, Aniththa Thivakaran, 181821

CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)

EHA Library, Frauke Theis, 181820

PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS

EHA Library, Pedro Casado, 181819

CLUSTER REGULATION OF RUNX FAMILY BY “GENE SWITCH” TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.

EHA Library, Ken Morita, 181818

ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2

EHA Library, Ruchi Pandey, 181817

PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.

EHA Library, Daniela Di Marcantonio, 181815

THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION

EHA Library, Robert Slany, 181814

DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS

EHA Library, Sharlene Adams, 181813

FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS CONVENTIONAL CHEMOTHERAPY

EHA Library, Matthias Stelljes, 181812

EXPOSURE-ADJUSTED ADVERSE EVENTS COMPARING BLINATUMOMAB WITH STANDARD OF CARE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY

EHA Library, Max S.Topp, 181811

KTE-C19 CHIMERIC ANTIGENRECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3

EHA Library, Bijal Shah, 181810

PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)

EHA Library, Frederick L. Locke, 181809

BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY

EHA Library, Franco Locatelli, 181808

A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS

EHA Library, Renato Bassan, 181807

PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN

EHA Library, Elias Jabbour, 181806

UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Nicholas Short, 181805

ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

EHA Library, Shannon Maude, 181804

FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS

EHA Library, Dr. Fabian Lang, 181803

SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL

EHA Library, Marina Kunstreich, 181802

TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Anne BUFFIERE, 181801

BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME

EHA Library, Lidia M Fernández-Sevilla, 181800

THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Ali Alhammer, 181799

CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS

EHA Library, Shu-Juan Wang, 181798

A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR

EHA Library, Africa Gonzalez-Murillo, 181797

CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA

EHA Library, Lucia Fernandez, 181796

PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING

EHA Library, Felix Seyfried, 181795

RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL

EHA Library, Yuan Kong, 181794

NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE - IMPACT OF AGE ON MUTATIONAL LOAD

EHA Library, Lisa Pleyer, 181845